Gabapentin Capsule
Product Images NDC 82868-051

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82868-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82868-051-30 (82868 051 30 Rev A 06 24)

Gabapentin Capsules USP 300 mg label for 30 capsules, prescription only. The label includes storage instructions to keep between 20-25°C with excursions allowed between 15-30°C, and advises to see the package insert for dosage. The product is distributed by Northwind Pharmaceuticals Inc. and labeled by Northwind Health Company, LLC.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period comparing placebo with Gabapentin at 3600 mg/day. The x-axis shows weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. Two phases are indicated: a 4-week dose titration period followed by a 4-week fixed dose period. The Gabapentin group shows a decreasing trend in pain scores compared to the placebo group.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain score over 7 weeks comparing placebo and two gabapentin groups (1800 mg/day and 2400 mg/day). The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups display a greater reduction in mean pain score compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14% to Gabapentin 1800 mg at 32% and GBP 2400 mg at 34%. Statistical significance is indicated with ** p < 0.01 and *** p < 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

This image displays a formula used for calculating creatinine clearance (CLCr). The formula incorporates variables such as age in years, weight in kilograms, serum creatinine in mg/dL, and includes a 0.85 multiplication factor for female patients. It is related to renal function assessment.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H) as part of the molecule.*

FDA Label Image

Image-09 (Image 09)

A scatter plot graph showing the percentage difference on the y-axis and daily dose in milligrams (600, 900, 1200, 1800 mg) on the x-axis. The graph compares results from three studies labeled a, b, and c, with distinct markers for each study. The data points show increasing percent difference with higher doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.